Last reviewed · How we verify
Gadovist
At a glance
| Generic name | Gadovist |
|---|---|
| Also known as | gadobutrol |
| Sponsor | Vanderbilt University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Magnetic resonance imaging
Common side effects
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Dotarem vs Gadobutrol Contrast for Breast MRI (PHASE4)
- A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients (PHASE2, PHASE3)
- Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- Novel Imaging Technique to Assess Gynecologic Cancer (PHASE1)
- Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease (NA)
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions (PHASE3)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadovist CI brief — competitive landscape report
- Gadovist updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI